Post-pancreatitis diabetes mellitus: investigational drugs in preclinical and clinical development and therapeutic implications

Author(s):  
Maxim S. Petrov
2016 ◽  
Vol 176 (12) ◽  
pp. 1826 ◽  
Author(s):  
Thomas J. Hwang ◽  
Daniel Carpenter ◽  
Julie C. Lauffenburger ◽  
Bo Wang ◽  
Jessica M. Franklin ◽  
...  

2021 ◽  
pp. 239936932098478
Author(s):  
Joana Marques ◽  
Patrícia Cotovio ◽  
Mário Góis ◽  
Helena Sousa ◽  
Fernando Nolasco

Diabetic nephropathy is a well known complication of diabetes mellitus and the leader cause of end -stage renal disease worldwide. Nonetheless, other forms of renal involvement can occur in diabetic population. Since it has prognostic and therapeutic implications, differentiating non-diabetic renal disease from diabetic nephropathy is of great importance. We report an 80-year-old man with well-controlled type 2 diabetes mellitus and hypertension, who presented with rapid deterioration of renal function, nephrotic proteinuria, microscopic hematuria and leukocyturia. The atypical clinical presentation prompted us to perform a kidney biopsy. A diagnosis of proliferative glomerulonephritis with monoclonal immunoglobulin deposits (light chain only variant) was made, with however some chronic histological aspects which made us took a conservative therapeutic attitude. We emphasize that other causes of chronic proteinuric kidney disease should be considered in patients with type 2 diabetes mellitus, based on clinical suspicion, absence of other organ damage and mostly if an atypical presentation is seen. We review the spectrum of monoclonal gammopathies of renal significance, focusing on this rare and newly describe entity.


2017 ◽  
Vol 08 (05) ◽  
Author(s):  
Md Tanjir Islam ◽  
Md Sahab Uddin ◽  
Kamrun Nahar Lucky ◽  
Md Manjurul Islam ◽  
Sheik Md Saiful Islam ◽  
...  

2014 ◽  
Vol 32 (1) ◽  
pp. 40-51 ◽  
Author(s):  
Michael Hay ◽  
David W Thomas ◽  
John L Craighead ◽  
Celia Economides ◽  
Jesse Rosenthal

2016 ◽  
Vol 397 (12) ◽  
pp. 1217-1222 ◽  
Author(s):  
Dorinne Desposito ◽  
Ludovic Waeckel ◽  
Louis Potier ◽  
Christine Richer ◽  
Ronan Roussel ◽  
...  

Abstract Genetic and pharmacological studies, clinical and experimental, focused on kallikrein-K1, kinin receptors and ACE/kininase II suggest that kinin release in the settings of ischemia or diabetes reduces organ damage, especially in the heart and kidney. Kinin bioavailability may be a limiting factor for efficacy of current kinin-potentiating drugs, like ACE inhibitors. Primary activation of kinin receptors by prototypic pharmacological agonists, peptidase-resistant, selective B1 or B2, displays therapeutic efficacy in experimental cardiac and peripheral ischemic and diabetic diseases. B1R agonism was especially efficient in diabetic animals and had no unwanted effects. Clinical development of kinin receptor agonists may be warranted.


Sign in / Sign up

Export Citation Format

Share Document